Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07610369 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Study acronym: PSI-PD
StatusRecruiting
PhasePhase 2
Started2026-07-10
View on ClinicalTrials.gov ↗

Amendment history

2026-07-16
Study Status, Contacts/Locations v2
Recruitment opened
Primary completion pushed: 2030-06 → 2030-07
Completion pushed: 2030-06 → 2030-07
Start date2026-06→2026-07
Study sitesdetails revised at 1 of 1 site
2026-06-24
Study Status v1
Primary completion pushed: 2030-05 → 2030-06
Completion pushed: 2030-05 → 2030-06
Start date2026-05→2026-06
2026-05-21
Original filing
Yale University
487 trials monitored
See 35 trials at risk
Depression
2,976 trials monitored
See 162 trials at risk
Parkinson's Disease
1,423 trials monitored
See 59 trials at risk
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Trial Details
NCT Number NCT07610369
Lead Sponsor Yale University
Collaborators: Michael J. Fox Foundation for Parkinson's Research
Conditions Depression, Parkinson's Disease (PD)
Enrollment 40 participants
Start Date 2026-07-10
Primary Completion 2030-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-09-28